COVID-19 jab maker BioNTech said Monday it would build a factory in Singapore that could produce hundreds of millions of doses of vaccines based on its mRNA technology per year in southeast Asia.
For more coronavirus news, visit our dedicated page.
Construction of the manufacturing plant and a regional headquarters in Singapore will start this year, and the site could become operational by 2023, the German company said in a statement.
Also Read
-
Pfizer-BioNTech files for full US approval of COVID-19 vaccine
Pfizer Inc and German partner BioNTech SA have filed for a full approval for their COVID-19 vaccine, which is now authorized only for emergency use, ... Coronavirus -
Pfizer, BioNTech apply to extend COVID-19 vaccine use for adolescents in EU
Pfizer Inc and partner BioNTech SE said on Friday they had applied to the European health regulator to extend the marketing authorization for their ... Coronavirus -
BioNTech expects vaccine trial results for babies, other EMA approvals soon
BioNTech expects results by September from trials testing the COVID-19 vaccine that it and Pfizer have developed in babies as young as six months old, ... Coronavirus
